Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of ...

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

Portsmouth’s leading workspace, has announced a new lettings agreement with Curium - the world-leading nuclear medicine ...

PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

After a breakdown in US-Russia relations, Riken finds itself ahead of its rivals. And Lawrence Berkeley National Laboratory ...

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Lantheus (LNTH – Research Report), with a price target ...

Learn more about whether Integra LifeSciences Holdings Corporation or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...

PYLCLARI ® is being produced by Curium at its facilities in Helsinki, Finland – ensuring distribution to Estonia, Finland, Latvia, and Sweden. For more information about PYLCLARI ®: www.pylclari.com ...